Join PER® September 15th for the New York Advanced Practice Collaborative Meeting! Directed toward NP/PAs, this meeting blends presentations on cutting-edge information with panel discussions to enhance learning.

General Discussions

Dr. Komrokji Discusses Myelodysplastic Syndromes

By Rami S. Komrokji, MD
PUBLISHED WEDNESDAY, DECEMBER 31, 1969
Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the risk factors for developing myelodysplastic syndromes(MDS).

Komrokji says the majority of the time, physicians don’t know why patients develop MDS. Researchers think that it is due to the process of aging and different environmental factors. There are also certain genetic components linked to MDS, but these are very rare. Smoking can also lead to the development of MDS, Komrokji says.

Patients can also develop MDS from being treated for chemotherapy for other diseases. Although researchers originally thought MDS from chemotherapy had to do with the damage of stem cells, Komrokji says new evidence suggests that these patients might have genetic alterations that make them predisposed.

Komrokji says there are no preventive measures set up for MDS, but perhaps in the future, researchers can better understand the disease and better identify patients who might be predisposed to developing this disease.

Start a discussion
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.